<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00299845</url>
  </required_header>
  <id_info>
    <org_study_id>PG-ped-LPZ-01</org_study_id>
    <nct_id>NCT00299845</nct_id>
  </id_info>
  <brief_title>Randomized Trial for Pharmacogenomics-based Proton Pump Inhibitor Therapy in Children</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>Osaka University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Osaka University</source>
  <brief_summary>
    <textblock>
      Proton pump inhibitors are administered to children as off-label use in Japan. The purpose of
      this study is to evaluate the effects of CYP2C19 genotypes on pharmacokinetic
      /pharmacodynamic profiles of PPI in children. The results will provide the beneficial
      information for the individualized medicine of PPI in children.
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <enrollment type="Actual">0</enrollment>
  <condition>Gastroesophageal Reflux</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lansoprazole</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with gastroesophageal reflux

          -  The patient's parent or guardian gives written informed consent including
             pharmacogenomic analysis

          -  The patient is willing and able to give assent to participate.

        Exclusion Criteria:

          -  Serious hepatic disease, pulmonary disease, renal disease and blood disorder

          -  Inadequate clinical conditions
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>1 Year</minimum_age>
    <maximum_age>15 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Junichi Azuma, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Graduate School of Pharmaceutical Sciences, Osaka University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Osaka University Hospital</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-0871</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <verification_date>September 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2006</study_first_submitted>
  <study_first_submitted_qc>March 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 7, 2006</study_first_posted>
  <last_update_submitted>October 10, 2012</last_update_submitted>
  <last_update_submitted_qc>October 10, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2012</last_update_posted>
  <keyword>gastroesophageal reflux</keyword>
  <keyword>children</keyword>
  <keyword>lansoprazole</keyword>
  <keyword>cytochrome P450 2C19 (CYP2C19)</keyword>
  <keyword>pharmacogenomics</keyword>
  <keyword>genetic polymorphisms</keyword>
  <keyword>individualized medicine</keyword>
  <keyword>pharmacokinetics/dynamics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lansoprazole</mesh_term>
    <mesh_term>Dexlansoprazole</mesh_term>
    <mesh_term>Proton Pump Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

